Moderna's stock surged 177%, hitting a three-and-a-half-year high; its mRNA cancer vaccine met its Phase III clinical trial endpoint—how significant is this breakthrough?

But this damn Moderna stock truly nearly killed me—so after the pandemic, I swore off pharmaceutical R&D stocks entirely. The waters run too deep; my expertise isn’t sufficient, and it’s easy to drown. Few people caught this rally today, so I don’t even feel FOMO. Even ‘Mad Dog’ remarked that the market has lost its mind. Setting aside that massive +177% green candle for a moment, the result itself today is genuinely high-impact. If you’ve forgotten the ‘great cold’ six years ago, let me first refresh your memory on what mRNA actually is. The core idea behind traditional vaccines is to expose the immune system to the enemy in advance. Inactivated vaccines are the most intuitive: essentially, they drag the virus’s ‘corpse’ before the immune system for facial recognition. mRNA, by contrast, operates more like programming—it doesn’t deliver the virus; it delivers instructions. Take the COVID-19 vaccine as an example: lipid nanoparticles (LNPs) encapsulate mRNA encoding the spike protein. Once inside cells, this mRNA directly hijacks the body’s own cellular machinery to produce the corresponding antigen, enabling the immune system to learn how to recognize it. [1] Thus, mRNA’s greatest engineering advantage is exceptionally straightforward: programmability. Change the sequence, and you change the instruction—while much of the underlying delivery system, manufacturing, and production process remains reusable. That’s precisely why COVID-19 was monumental for the entire mRNA industry. Research into mRNA cancer vaccines has spanned decades; Moderna’s pipeline in this area had already begun pre-pandemic. COVID-19 accomplished something no company could ever have funded independently: it subjected this entire technology platform to the largest-scale stress test in human history. [2] Billions of doses were produced, transported, stored, administered, and monitored for pharmacovigilance—every step rigorously validated. Now, returning to cancer: many things suddenly become simpler. Cancer’s toughest challenge lies in its origin—it’s *you*. Viruses invade from outside; the immune system instinctively recognizes many foreign elements as suspicious. Cancer cells, however, evolve gradually from our own cells—and further evade immune surveillance and suppress T-cell activity through multiple mechanisms. Traditional cytotoxic therapies—like many chemotherapies—essentially rely on cancer cells being slightly more vulnerable to such toxicity than healthy tissue, resulting in a frequently narrow therapeutic window. Targeted drugs are far more precise, yet still confront major hurdles: difficulty identifying suitable targets, tumor heterogeneity, drug resistance, and pathway bypass, among others. What Moderna and Merck achieved today, by contrast, adopts a refreshingly ‘coder-like’ approach. Intismeran—also known as V940 or mRNA-4157—is an individualized neoantigen therapy (INT).

U.S. healthcare and biotech stocks went wild this week—what’s behind Moderna’s (MRNA) 177% one-day surge, and how should we view the outlook going forward?

This week, U.S. healthcare and biotech stocks went wild—MRNA (Moderna) surged 177% in a single day. The reason for the sharp price jump is that Moderna and Merck announced positive results from their jointly developed personalized mRNA cancer vaccine in a Phase III clinical trial. After reviewing several sources, here’s a general overview of this vaccine: Called intismeran autogene—or alternatively V940 or mRNA-4157—the vaccine targets high-risk melanoma, a deadly form of skin cancer. Even after surgical removal of the tumor, many patients face a high likelihood of recurrence or metastasis. Here’s how the vaccine works: physicians first take a sample of the patient’s tumor and identify the unique genetic mutations driving *that specific* cancer. Moderna then custom-designs a personalized vaccine based on those mutations. The goal? To train the patient’s immune system to recognize the cancer—and subsequently eliminate those malignant cells.

BioNexus Gene Lab Corp Stock Price Updates to $1.510

Jul 24, 2026

BioNexus Gene Lab Corp, a biotechnology firm specializing in chemical solutions and diagnostics, reports stock trading sideways near $1.510 with healthy fundamentals despite short-term bearish indicators.

TradingKey

2026-05-12

BioNexus Gene Lab Corp (BGLC)

2026-06-18

BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates

2026-06-18

BioNexus Gene Lab Corp (BGLC) Institutional Confidence

2026-06-18

BioNexus Gene Lab Corp (BGLC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

2026-06-18

BioNexus Gene Lab Corp Announces 10-to-1 Merger Stock Split